Neuro-oncology最新文献

{"title":"Revisiting baseline 18F-FDG PET/CT parameters: Key considerations for prognostic evaluation in primary CNS lymphoma.","authors":"Minyoung Oh, Hyungwoo Cho, Dok Hyun Yoon, Jae Seung Kim","doi":"10.1093/neuonc/noaf052","DOIUrl":"10.1093/neuonc/noaf052","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1402-1403"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuro-oncological superiority of supratotal resection in lower-grade gliomas.","authors":"Alberto L Gallotti, Marco Rossi, Marco Conti Nibali, Tommaso Sciortino, Lorenzo G Gay, Guglielmo Puglisi, Antonella Leonetti, Francesco Bruno, Roberta Rudà, Riccardo Soffietti, Gabriella Cerri, Lorenzo Bello","doi":"10.1093/neuonc/noae264","DOIUrl":"10.1093/neuonc/noae264","url":null,"abstract":"<p><strong>Background: </strong>Supratotal-resection (SpTR) is a promising surgical strategy in lower-grade gliomas (LGGs). SpTR assessment, feasibility and distinctive features, as well as clinical benefit at first and second surgery and on overall survival must be better characterized. The critical percentage of resection exceeding FLAIR margins to obtain clinical benefit and its impact on long-term functional performance are also undefined.</p><p><strong>Methods: </strong>Included were 704 patients with primary and 439 with recurrent LGGs seen between 2010 and 2019, who underwent resection with brain-mapping technique (BMT) aimed at achieving a SpTR without any \"a-priori\" selection. Extent-of-resection, evaluated on 3D-FLAIR-MR and categorized according to residual tumor and cavity volume, was associated with progression-free survival (PFS) and malignant(M)PFS at first and second surgery and overall survival by univariate, multivariate, and propensity-score analysis. Functional performance was assessed by neuropsychological (NPS) evaluation.</p><p><strong>Results: </strong>SpTR evaluation requires volumetric assessment enhanced by brain deformation measurement in parietal tumors; SpTR rate accounts on average for 50.2% and 35.7% at first and second surgery is higher in grade-2, frontal, and temporal locations (at expenses of total resection [TR]). Compared to TR, SpTR reduces and postpones first and second recurrences in all molecular subtypes and grades, delays MPFS without difference in rate, and prolongs overall survival (OS). A degree of SpTR > 120% associates with the lowest recurrence risk. SpTR associates with the best NPS longitudinal course.</p><p><strong>Conclusions: </strong>This study supports the feasibility of SpTR in LGGs, its benefit at first and second surgery regardless of molecular subtypes, and on OS, significantly reducing recurrence when SpTR > 120%; SpTR also associates with the best patients' functional outcome.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1270-1284"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanopore sequencing as a cutting-edge technology for medulloblastoma classification.","authors":"Mathilde Filser, Jacob Torrejon, Kevin Merchadou, Christelle Dufour, Elodie Girard, Christine Bourneix, Elisa Lemaître, Tarek Gharsalli, Riwan Brillet, Jennifer Wong, David Gentien, Audrey Rapinat, Nicolas Servant, Alexandre Vasiljevic, Anne Isabelle Bertozzi, Sandra Raimbault, Arnault Tauziede Espariat, Benoit Lhermitte, Cécile Faure-Conter, Céline Icher, Claire Berger, Claude Alain Maurage, Damien Bodet, David Meyronet, Emmanuelle Uro-Coste, Emilie De Carli, Fabien Forest, Gilles Palenzuela, Guillaume Chotard, Guillaume Gauchotte, Helene Sudour, Ludovic Mansuy, Marianna Deparis, Matthias Tallegas, Maxime Faisant, Natacha Entz-Werle, Pascale Varlet, Pierre Leblond, Sophie Michalak-Provost, Stéphanie Proust Houdemont, Valérie Rigau, François Doz, Olivier Delattre, Franck Bourdeaut, Olivier Ayrault, Julien Masliah-Planchon","doi":"10.1093/neuonc/noae279","DOIUrl":"10.1093/neuonc/noae279","url":null,"abstract":"<p><strong>Background: </strong>Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into 4 molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis. It is critical to establish effective subtyping methods for accurate diagnosis and patient's management that strikes a delicate balance between improving outcomes and minimizing the risk of comorbidities.</p><p><strong>Methods: </strong>We evaluated the ability of Nanopore sequencing to provide clinically relevant methylation and copy number profiles of MB. Nanopore sequencing was applied to an EPIC cohort of 44 frozen MB, benchmarked against the gold standard EPIC array, and further evaluated on an integrated diagnosis cohort of 116 MB.</p><p><strong>Results: </strong>Most MB of both cohorts (42/44; 95.5% and 106/116; 91.4%, respectively) were accurately subgrouped by Nanopore sequencing. Employing Flongle flow cells for 18 MB allowed a more rapid and cost-effective analysis, with 94.4% (17/18) being correctly classified. Nanopore sequencing enabled us to accurately subtype 28/30 (93.3%) MB.</p><p><strong>Conclusion: </strong>This study, conducted on the largest cohort of MB analyzed with Nanopore sequencing to date, establishes the proof of concept that this modern and innovative technology is well-suited for MB classification. Nanopore sequencing demonstrates a robust capacity for precise subtyping of MB, a critical advancement that holds significant potential for enhancing patient stratification in future clinical trials. Its ability to deliver quick and cost-effective results firmly establishes it as a game-changer in the field of MB classification.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1313-1324"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can baseline 18F-FDG PET/CT predict the prognosis of primary CNS lymphoma?","authors":"Huiying Zhu, Yaping Luo, Wei Zhang, Daobin Zhou, Yan Zhang","doi":"10.1093/neuonc/noaf050","DOIUrl":"10.1093/neuonc/noaf050","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1399-1401"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the Pediatric Brain Tumor Atlas and Pediatric Neuro-Oncology Consortium.","authors":"Ryan J Corbett, Cricket C Gullickson, Zhuangzhuang Geng, Miguel A Brown, Bo Zhang, Chuwei Zhong, Nicholas Van Kuren, Antonia Chroni, Christopher Blackden, Ammar S Naqvi, Alexa Plisiewicz, Sean McHugh, Emmett Drake, Kaitlin Lehmann, Tom B Davidson, Michael Prados, Phillip B Storm, Adam C Resnick, Angela J Waanders, Sebastian M Waszak, Sabine Mueller, Jo Lynne Rokita, Cassie Kline","doi":"10.1093/neuonc/noaf017","DOIUrl":"10.1093/neuonc/noaf017","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system (CNS) tumors lead to cancer-related mortality in children. Genetic ancestry-associated cancer prevalence and outcomes have been studied but are limited.</p><p><strong>Methods: </strong>We performed genetic ancestry prediction in 1,452 pediatric patients with paired normal and tumor whole genome sequencing from the Open Pediatric Cancer (OpenPedCan) project to evaluate the influence of reported race and ethnicity and ancestry-based genetic superpopulations on tumor histology, molecular subtype, survival, and treatment.</p><p><strong>Results: </strong>Predicted superpopulations included African (AFR, N = 153), Admixed American (AMR, N = 222), East Asian (EAS, N = 67), European (EUR, N = 968), and South Asian (SAS, N = 42). Reported race and ethnicity and ancestry-based genetic superpopulations were non-randomly associated (P < .001). Patients with an atypical teratoid rhabdoid tumor or meningioma were enriched for AFR ancestry (OR = 2.6, FDR = 0.01; OR = 2.9, FDR = 0.01, respectively). Among KIAA1549::BRAF fusion-positive low-grade glioma (LGG) diagnoses, EAS and SAS patients disproportionately harbored exon 15:09 breakpoints (FDR < 0.05), and AMR patients demonstrated rare breakpoints, which were associated with lesser degree of surgical resection and worse event-free survival (EFS) versus other breakpoints (hazard ratio (HR) = 4.6, P = .03). Non-EUR and AMR patients with germ cell tumors and SHH-activated medulloblastoma, respectively, exhibited worse EFS relative to EUR patients (HR = 12.1, P < .01; HR = 5.2, P = .03) and AFR patients with LGG (HR = 16.4, P < .01) or ependymoma (HR = 5.5, P = .02) had worse overall survival compared to EUR patients. We observed a higher frequency of clinical trial enrollment among AMR patients across tumor histologies (OR = 2.0, P ≤ .01), but increased utilization of photon versus proton radiation relative to other superpopulations (OR = 0.55, P= .04).</p><p><strong>Conclusions: </strong>Genetic ancestry-associated differences exist across pediatric CNS tumor histological and molecular subtypes from PBTA and PNOC. Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1356-1371"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An opportunity to impact anxiety in family caregivers of persons with a primary malignant brain tumor.","authors":"Paula R Sherwood","doi":"10.1093/neuonc/noaf048","DOIUrl":"10.1093/neuonc/noaf048","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1133-1134"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.","authors":"Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof, Sébastien Perreault, Olaf Witt, David S Ziegler, Pablo Hernáiz Driever, Andrea T Franson, Patricia A Baxter, Nicholas S Whipple, Cassie Kline, Devorah Segal, Nada Jabado, Simon Bailey, Geoffrey McCowage, Jordan R Hansford, Dong-Anh Khuong-Quang, Nicholas G Gottardo, Timothy Hassall, Jung Woo Han, Michal Yalon Oren, Susan N Chi, Jiaheng Qiu, Daniel Da Costa, Sandya Govinda Raju, Peter Manley, Darren Hargrave","doi":"10.1093/neuonc/noae274","DOIUrl":"10.1093/neuonc/noae274","url":null,"abstract":"<p><strong>Background: </strong>Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.</p><p><strong>Methods: </strong>FIREFLY-1 investigated the efficacy (arm 1, n = 77), safety, and tolerability (arms 1/2) of tovorafenib (420 mg/m2 once weekly; 600 mg maximum) in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma (pLGG). In this post hoc analysis, anti-tumor activity and VA were analyzed in arm 1 patients with OPG. Anti-tumor activity was independently assessed per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG), Response Assessment in Pediatric Neuro-Oncology-LGG (RAPNO), and RANO-LGG criteria. The data cutoff was June 5, 2023.</p><p><strong>Results: </strong>Forty-two of 77 patients had OPGs; 35 of 42 had ≥2 VA assessments. The overall response rate in the OPG subgroup according to RANO-HGG, RAPNO, and RANO-LGG criteria were 64%, 50%, and 55%, with clinical benefit rates of 95%, 88%, and 90%, respectively. VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving. The safety profile in the arm 1 OPG subgroup was similar to the overall FIREFLY-1 safety analysis set.</p><p><strong>Conclusions: </strong>Tovorafenib demonstrated anti-tumor activity in relapsed/refractory BRAF-altered OPG across radiological assessment criteria and was generally well tolerated. Importantly, vision remained stable or improved in most patients.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1341-1355"},"PeriodicalIF":16.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cranial radiotherapy profoundly affects glia without inducing widespread cellular senescence.","authors":"L E Kuil, R H van Scheppingen, Y M Leter, B H Röring, M C de Gooijer, C L van Heijningen, S Prekovic, A Compter, O van Tellingen, S B Schagen","doi":"10.1093/neuonc/noaf146","DOIUrl":"https://doi.org/10.1093/neuonc/noaf146","url":null,"abstract":"<p><strong>Background: </strong>More than 70% of cancer patients who underwent cranial radiotherapy have cognitive problems, suggesting that they might undergo accelerated brain aging due to the cancer treatment. Radiotherapy is known to induce cellular senescence in tumors and in various cell types in vitro. Therefore, we hypothesized that cranial radiotherapy induces cellular senescence in the brain.</p><p><strong>Methods: </strong>We treated male C57BL/6 mice with various dosages of (fractionated) CT-guided cranial radiotherapy. The brains were analyzed for various senescence and glial markers using immunohistochemistry, histochemistry, Cosmx SMI and RT-qPCR. To contextualize the findings regarding cranial radiotherapy in young animals and assess whether these changes parallel natural aging, we studied the brains from 77-week-old female mice, which is considered middle-aged to old representing early aging.</p><p><strong>Results: </strong>Surprisingly, we found no increase in markers for cellular senescence in the brain after cranial radiotherapy. However, we did detect profound changes in different types of glia. In early-aged mice we again did not detect an increase in senescence markers, but we observed the same directionality in the effects on glia. These effects on glia were milder compared to those upon cranial radiotherapy.</p><p><strong>Conclusion: </strong>Overall, cellular senescence in the healthy brain seems a rather uncommon phenomenon and not induced upon cranial radiotherapy, but profound changes in different types of glia were detected upon cranial radiotherapy.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastoma.","authors":"Qing You Pang, Wisna Novera, Lynnette Wei Hsien Koh, Yuk Kien Chong, See Wee Lim, Ngak Leng Sim, Simone Rizzetto, Jinyue Liu, Xuling Lin, Samantha Ya Lyn Ang, Justin Rui-Xin Ker, Kai-Rui Wan, David Chyi Yeu Low, Marija Cvijovic, Wilson Wen Bin Goh, Huilin Shao, Nguan Soon Tan, Stephen Yip, Anders Martin Jacobsen Skanderup, Patrick Tan, Carol Tang, Beng Ti Ang","doi":"10.1093/neuonc/noaf145","DOIUrl":"https://doi.org/10.1093/neuonc/noaf145","url":null,"abstract":"<p><strong>Background: </strong>Multi-omics profiling of glioblastoma (GBM) has unravelled two aspects fundamental to its aggressiveness and lethality that is molecular heterogeneity inherent to the tumour and cellular plasticity modulated by microenvironment. Yet, empirical validation to identify causal factors for these complex mechanisms is rather scarce. Here, we report our endeavour in establishing Glioportal, a GBM tumour biobank with derivative preclinical models and molecular information that we leverage for basic and translational research on precision therapies.</p><p><strong>Methods: </strong>Bulk transcriptome and single-cell-based deconvolution analyses highlighted key features of distinct GBM subtypes and ligand-receptor pairs predicted to regulate malignant cell states plasticity. Synthetic genetic tracing tool and target genes/proteins expression analyses validated ligands-induced mesenchymal transition. This was further corroborated with phenotypic invasion/migration assays and cell-based assays using inhibitors, functional antibodies and gene silencing approaches. Proof-of-concept animal experiment was conducted using orthotopic xenograft carrying gene knockdown. Clinical relevance was assessed through immunohistochemical assay.</p><p><strong>Results: </strong>Our transcriptomic analysis highlights the integral roles of STAT3 and NF-κB pathways in maintaining intrinsic mesenchymal identity and enabling myeloid-induced plasticity towards mesenchymal phenotype. One critical ligand, TNF, confers mesenchymal adaptation and cellular invasiveness that is mitigated by TNFRSF1A, but not TNFRSF1B, loss of function. TNFRSF1A silencing significantly improves survival in vivo.</p><p><strong>Conclusion: </strong>Glioportal makes a valuable resource for identifying therapeutic vulnerabilities in molecularly stratified GBM. Here, we underscore GBM dependency on myeloid-derived ligands to acquire mesenchymal traits that has clinical implications in therapeutic response and recurrence. Such reliance warrants treatment strategies targeting ligand-receptor pairs to mitigate interactions with tumour ecosystem.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Years of life lost due to central nervous system tumor subtypes in the United States.","authors":"Jakob V E Gerstl, Mackenzie Price, Joshua D Bernstock, Carol Kruchko, Lennard Spanehl, Paramesh V Karandikar, Jill S Barnholtz-Sloan, Timothy R Smith, Elizabeth B Claus, Quinn T Ostrom","doi":"10.1093/neuonc/noaf142","DOIUrl":"https://doi.org/10.1093/neuonc/noaf142","url":null,"abstract":"<p><strong>Background: </strong>Years of Life Lost (YLL) is a disease burden measure quantifying the number of years lost due to premature mortality for a given disease. The present study sought to assess YLL for primary brain and other central nervous system (CNS) tumor histopathologies in the United States.</p><p><strong>Methods: </strong>Mortality, incidence, and life expectancy data for mortalities occurring in 2018 were obtained from the National Vital Statistics System and the National Program of Cancer Registries. Tumor specific YLL was estimated by subtracting age of death from projected life expectancy; mean YLL (mYLL) was determined to assess the impact of CNS tumor diagnosis on the individual patient level.</p><p><strong>Results: </strong>For mortalities occurring in 2018, the total YLL due to malignant CNS tumors was 364,223 years (mYLL = 21.2 years), compared to 15,472 years (mYLL = 14.2 years) for non-malignant tumors. Glioblastoma had the highest total YLL amongst malignant CNS tumors (58.8% of all primary CNS tumor YLL; mYLL = 19.8 years), and non-malignant meningioma amongst non-malignant CNS tumors (2.9% of all primary CNS tumor YLL; mYLL = 14.4 years). Malignant pediatric tumors had the greatest mYLL, with medulloblastoma having a mYLL of 61.2 years and other embryonal tumors a mYLL of 50.7.</p><p><strong>Conclusions: </strong>Malignant CNS tumors, glioblastoma in particular, contributed the most to total YLL, whereas pediatric CNS malignancies had the greatest mYLL. Used with other epidemiological data, the authors contend that this quantification may help rationalize allocation of clinical and research resources.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}